---
title: Pantherna Therapeutics
date: 2019-07-03T08:09:23Z
modified: 2026-08-12T06:59:42Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/pantherna-therapeutics/"
type: portfolio
status: publish
excerpt: ""
wpid: 72411
language:
  - English
post_translations:
  - pll_5d1c62ad37440
branchen22:
  - Cardiology / Cardiovascular
sectors:
  - Pharmaceuticals
focus_areas:
  - Drug Delivery
timestamp: 2026-08-12T06:59:42Z
tags:
  - English
  - pll_5d1c62ad37440
  - Cardiology / Cardiovascular
  - Pharmaceuticals
  - Drug Delivery
---

## Beschreibungstext

Pantherna Therapeutics is a wholly owned subsidiary of T-CURX GmbH, Würzburg, and based in Hennigsdorf (Brandenburg), Germany . Pantherna’s proprietary platform focuses on the development of advanced lipid nanoparticle (PTX\_LNP) technology for targeted and cell-selective delivery of nucleic acids, including its propriertary PTXmRNA molecules. Pantherna´s technology offers solutions for next-generation cell engineering approaches, supporting both ex vivo and in vivo applications, such as emerging in vivo CAR-T strategies, opening new avenues for innovative therapies in oncology and beyond.

## Unternehmenswebsite

> [Home](https://www.pantherna-therapeutics.com/)

## Adresse

Neuendorfstrasse 20b
16761 Hennigsdorf

## Kontakt

Array